The German Standing Vaccination Commission recommends that people under the age of 60 for a should receive an RNA vaccine such as that from BioNTech for their second vaccination.
It will be recommended “that these people receive their second, so-called heterologous, vaccination with an RNA vaccine such as BioNTech. Animal experiment data show that the immune reaction is the same after heterologous vaccination,” said the head of the Standing Vaccination Commission, Thomas Mertens, in an interview with the news magazine Spiegel.
